Shukla V K, Turndorf H, Bansinath M
Department of Anesthesiology, School of Medicine, New York University Medical Center, NY 10016, USA.
Eur J Pharmacol. 1995 Mar 16;292(3-4):293-9. doi: 10.1016/0926-6917(95)90035-7.
In mice pretreated intracerebroventricularly (i.c.v.) with either saline (10 microliters/mouse), pertussis (1 microgram/mouse) or cholera (2.5 micrograms/mouse) toxins, effect of kappa-opioid receptor agonists on the colonic temperature and charcoal meal transit time were assessed. The kappa-opioid receptor agonist, trans-(+)-3,4-dichloro-N-methyl-[2-(1- pyrrolidinyl)cyclohexyl]-benzeneacetamide methane sulfonate hydrate (U-50488H, 50, 100 and 200 micrograms/mouse, i.c.v.) produced dose dependent hypothermia. Pertussis toxin pretreatment (72 and/or 144 h before) antagonized (P < 0.05) the hypothermic effect of U-50488H (100 micrograms/mouse) and (+)-trans-N-methyl-N-[2-(1- pyrrolidinyl)cyclohexyl[benz[b]-thio-phene-4-acetamide (PD 117302, 30 micrograms/mouse). In contrast, cholera toxin pretreatment (48 and/or 96 h before) did not antagonize the hypothermic effect of the kappa-opioid receptor agonists. Moreover, both i.c.v. and intrathecal (i.t.) administration of kappa-opioid receptor agonists, U-50488H, }[5R-(5 alpha,7 alpha,8 beta)]-(+/-)-N-methyl-N-[7-(1- pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl]-benzeneacetamide¿ (U-69593) and PD 117302, produced dose dependent inhibition of the charcoal meal transit. Cholera toxin pretreatment (48 and 96 h before) augmented (P < 0.05) the antitransit effect of i.c.v. administered U-50488H (100 micrograms/mouse), U-69593 (100 micrograms/mouse) and PD 117302 (50 micrograms/mouse). However, pertussis toxin pretreatment did not affect the gastrointestinal inhibitory effect of the kappa-opioid receptor agonists. The present results extend our previous results on the effect of kappa-selective agonists on gastrointestinal motility and indicate, like the prototype opiate agonist morphine, kappa-opioid receptor agonists are effective in inhibiting the gastrointestinal motility when administered either by intrathecal or intracerebroventricular routes.(ABSTRACT TRUNCATED AT 250 WORDS)
对预先经脑室注射(i.c.v.)给予生理盐水(10微升/只小鼠)、百日咳毒素(1微克/只小鼠)或霍乱毒素(2.5微克/只小鼠)的小鼠,评估κ-阿片受体激动剂对结肠温度和炭末推进时间的影响。κ-阿片受体激动剂反式-(+)-3,4-二氯-N-甲基-[2-(1-吡咯烷基)环己基]-苯乙酰胺甲磺酸盐一水合物(U-50488H,50、100和200微克/只小鼠,i.c.v.)产生剂量依赖性体温降低。百日咳毒素预处理(72小时和/或144小时前)拮抗(P<0.05)U-50488H(100微克/只小鼠)和(+)-反式-N-甲基-N-[2-(1-吡咯烷基)环己基][苯并[b]噻吩-4-乙酰胺(PD 117302,30微克/只小鼠)的降温作用。相反,霍乱毒素预处理(48小时和/或96小时前)不拮抗κ-阿片受体激动剂的降温作用。此外,i.c.v.和鞘内(i.t.)给予κ-阿片受体激动剂U-50488H、[5R-(5α,7α,8β)]-(±)-N-甲基-N-[7-(1-吡咯烷基)-1-氧杂螺[4,5]癸-8-基]-苯乙酰胺(U-69593)和PD 117302,均产生剂量依赖性抑制炭末推进。霍乱毒素预处理(48小时和96小时前)增强(P<0.05)i.c.v.给予的U-50488H(100微克/只小鼠)、U-69593(100微克/只小鼠)和PD 117302(50微克/只小鼠)的抗推进作用。然而,百日咳毒素预处理不影响κ-阿片受体激动剂对胃肠道的抑制作用。本研究结果扩展了我们先前关于κ-选择性激动剂对胃肠动力影响的结果,并表明,与原型阿片类激动剂吗啡一样,κ-阿片受体激动剂经鞘内或脑室注射给药时,可有效抑制胃肠动力。(摘要截短于250字)